What Happened

BrainChild Bio, a biotech startup originating from Seattle Children’s Hospital, secured $116M in Series A funding. The round was led by Seattle Children’s Hospital and WRF Capital. The funds will advance CAR-T therapies for pediatric brain cancers, including a pivotal phase 2 trial for diffuse intrinsic pontine glioma (DIPG) and a phase 1 trial for glioblastoma.

Who Is Affected

The funding directly impacts BrainChild Bio’s operations, enabling them to progress clinical trials for DIPG and glioblastoma. Pediatric patients with these cancers, who currently lack effective treatments, stand to benefit from these advancements. Investors like WRF Capital and Seattle Children’s Hospital are also key stakeholders.

Market Impact

• BrainChild Bio’s funding highlights growing investor interest in CAR-T therapies for solid tumors.
• The company’s focus on pediatric cancers addresses a critical unmet medical need.
• This funding positions BrainChild Bio as a potential leader in CAR-T therapies for brain cancers.

What to Watch

Monitor BrainChild Bio’s progress in its phase 2 trial for DIPG and phase 1 trial for glioblastoma. The company’s innovative approach to CAR-T therapies, including multiple-dose regimens, could set new standards in the field. Additionally, watch for potential partnerships or collaborations as BrainChild scales its operations.

Related coverage

• Elucid Raises $55M Series D to Expand AI Heart Care Platform
• Moleculin Biotech updates Annamycin data, prices stock offering at $0.75
• Saudi Biotech Fund IB Ventures Launches With $50 Million Raise
• Vaxart Updates BARDA Funding Award for COVID-19 Oral Pill Vaccine Trial